SNM Comments on Palmetto’s Policy Change for Rubidium, Rb-82

June 22, 2011

On Monday June 20th, the Society of Nuclear Medicine signed a joint statement sent to Palmetto GBA, inquiring about their recently revised reimbursement policy for the radiopharmaceutical, Rb82 rubidium, diagnostic, per study dose, up to 60 millicuries.

The statement, cosigned by the Society of Nuclear Medicine, the American College of Nuclear Medicine, the American Society of Nuclear Cardiology, and the American College of Cardiology, is specifically concerned that Palmetto has not only elected to modify their policy for how they will reimburse for these radiopharmaceuticals, but that the policy has been made retroactive and providers are now required to remit “overpayments” for the period of April 1, 2009 through March 15, 2011.

For further information or to acquire sample educational materials, please contact Jesse Schoolnik at


Joint Letter to Palmetto GBA